Scott Kinlay, Ph.D., M.B.,B.S.
This page shows the publications Scott Kinlay has written about C-Reactive Protein.
Role of C-reactive protein when prescribing a statin. Curr Atheroscler Rep. 2012 Feb; 14(1):26-32.
Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol. 2008 Jan; 28(1):142-7.
Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol. 2007 May 22; 49(20):2003-9.
Inflammatory biomarkers in stable atherosclerosis. Am J Cardiol. 2006 Dec 04; 98(11A):2P-8P.
Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol. 2002 May 15; 89(10):1205-7.
Relationship of antihypertensive treatment to plasma markers of vascular inflammation and remodeling in the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis study. Am Heart J. 2012 Apr; 163(4):735-40.
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003 Sep 30; 108(13):1560-6.
Effects of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Cardiol. 2003 Feb 20; 91(4A):9B-13B.
Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study. J Am Heart Assoc. 2013 Jan 28; 2(1):e003103.
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.